The latest data published by Eurostat on 28 April 2026 sheds new light on the scale of the impact that exports of pharmaceutical products have on the labour market of the Old Continent. In 2023, sales of medicines and pharmaceutical goods to countries outside the Union supported the employment of as many as 926,000 people, which underscores the strategic importance of an industry that not only generates direct jobs in specialised production plants and research laboratories, but also creates a multiplier effect that ripples through the entire economy.
This phenomenon has both a direct and an indirect dimension. Directly, 325,000 Europeans engaged in production, research and development, and distribution to global markets found work in the pharmaceutical sector. The remaining 601,000 positions are the result of supply chains and cooperative links, from suppliers of active substances, through logistics and packaging companies, to the specialised services sector, including the IT services that support research processes or international marketing.
In 2010, pharmaceutical exports generated employment for 504,000 people. Over the course of thirteen years that figure has nearly doubled, which represents an impressive increase in the context of the challenges facing the European economy - the ageing of societies, competitive pressure from Asia, and the energy and digital transformation. This trend reflects not only the growing global demand for high-quality European medicines, but also the success of investment strategies focused on innovation. European pharmaceutical corporations, drawing on a strong scientific base, regulations that ensure high quality standards, and access to the single market, have managed to consolidate their position on the world stage.
The geographical directions of these exports are of particular significance. The greatest impact on employment comes from trade with the United States, where demand for European pharmaceutical products translated in 2023 into support for 275,000 jobs on the European continent. Across the ocean lies one of the most demanding and at the same time wealthiest markets, one that places a high value on innovation and pharmacological safety. The next positions were taken by Switzerland with 104,000 and dynamically developing China with 103,000. These two directions illustrate, on the one hand, traditional ties with countries at a high level of technological development and, on the other, the growing importance of emerging markets. The United Kingdom and Japan are not without significance either, although their contribution is somewhat smaller.
Such a geographical distribution carries both opportunities and strategic challenges. Dependence on a handful of key trading partners underscores the need to diversify export directions, something that takes on particular significance in the context of geopolitical tensions, from the US-China trade war to the consequences of Brexit. At the same time, a strong position in the export of high value-added products such as pharmaceuticals constitutes for the European Union an important element in building strategic economic autonomy. At a time when many production sectors are being offshored to Asia, the pharmaceutical industry remains a bastion of European specialisation in knowledge, technology and quality.
Growing pressure to lower the cost of medicines from governments and insurers, the shortening of patent protection periods, the growth of generic production in countries with lower labour costs, and the rising role of biotechnology and personalised therapies - all of these factors may in the future affect the structure and scale of European exports. Moreover, global supply chains for pharmaceutical raw materials remain vulnerable to disruption, as the COVID-19 pandemic demonstrated. In this context, the European Union's industrial policy, including initiatives such as the European Health Union and programmes supporting research and development, takes on a strategic dimension.
